Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share

Regen BioPharma Inc

• Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.
• Potential dilution: number of shares indeterminable; as of April 17, 2026, common shares outstanding ~402.9M; CEO David Koos is a creditor and will be paid after one year.
• Created Series N Preferred Stock: 1,000 shares authorized, each with 75 million votes, enabling concentrated voting control.
• Changed auditor: BCRG replaced by Simon & Edward LLP after acquisition; no disagreements, but prior reports had going concern qualification.